Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 2
2001 4
2002 2
2003 10
2004 1
2005 9
2006 13
2007 7
2008 7
2009 11
2010 8
2011 5
2012 7
2013 6
2014 13
2015 16
2016 19
2017 26
2018 21
2019 15
2020 21
2021 20
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

220 results
Results by year
Filters applied: . Clear all
Page 1
Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.
Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J, Pölönen P, Hohtari H, Saeed K, Hannunen T, Ellonen P, Steinberger P, Kankainen M, Aittokallio T, Keränen MAI, Korhonen M, Mustjoki S. Dufva O, et al. Among authors: aittokallio t. Blood. 2020 Feb 27;135(9):597-609. doi: 10.1182/blood.2019002121. Blood. 2020. PMID: 31830245 Free PMC article.
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J. Kauko O, et al. Among authors: aittokallio t. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. doi: 10.1126/scitranslmed.aaq1093. Sci Transl Med. 2018. PMID: 30021885 Free PMC article.
Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.
Haikala HM, Anttila JM, Marques E, Raatikainen T, Ilander M, Hakanen H, Ala-Hongisto H, Savelius M, Balboa D, Von Eyss B, Eskelinen V, Munne P, Nieminen AI, Otonkoski T, Schüler J, Laajala TD, Aittokallio T, Sihto H, Mattson J, Heikkilä P, Leidenius M, Joensuu H, Mustjoki S, Kovanen P, Eilers M, Leverson JD, Klefström J. Haikala HM, et al. Among authors: aittokallio t. Nat Commun. 2019 Feb 6;10(1):620. doi: 10.1038/s41467-019-08541-2. Nat Commun. 2019. PMID: 30728358 Free PMC article.
Novel activities of safe-in-human broad-spectrum antiviral agents.
Ianevski A, Zusinaite E, Kuivanen S, Strand M, Lysvand H, Teppor M, Kakkola L, Paavilainen H, Laajala M, Kallio-Kokko H, Valkonen M, Kantele A, Telling K, Lutsar I, Letjuka P, Metelitsa N, Oksenych V, Bjørås M, Nordbø SA, Dumpis U, Vitkauskiene A, Öhrmalm C, Bondeson K, Bergqvist A, Aittokallio T, Cox RJ, Evander M, Hukkanen V, Marjomaki V, Julkunen I, Vapalahti O, Tenson T, Merits A, Kainov D. Ianevski A, et al. Among authors: aittokallio t. Antiviral Res. 2018 Jun;154:174-182. doi: 10.1016/j.antiviral.2018.04.016. Epub 2018 Apr 23. Antiviral Res. 2018. PMID: 29698664 Free PMC article. Review.
Genome-wide off-targets of drugs: risks and opportunities.
Giri AK, Ianevski A, Aittokallio T. Giri AK, et al. Among authors: aittokallio t. Cell Biol Toxicol. 2019 Dec;35(6):485-487. doi: 10.1007/s10565-019-09491-7. Epub 2019 Aug 20. Cell Biol Toxicol. 2019. PMID: 31432301 No abstract available.
JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL.
Wahnschaffe L, Braun T, Timonen S, Giri AK, Schrader A, Wagle P, Almusa H, Johansson P, Bellanger D, López C, Haferlach C, Stern MH, Dürig J, Siebert R, Mustjoki S, Aittokallio T, Herling M. Wahnschaffe L, et al. Among authors: aittokallio t. Cancers (Basel). 2019 Nov 21;11(12):1833. doi: 10.3390/cancers11121833. Cancers (Basel). 2019. PMID: 31766351 Free PMC article.
220 results